Vitamin C: Essential, Useful for Deficiency, and the Megadose Myth

Summary

Vitamin C is genuinely essential — humans cannot make it, deficiency causes scurvy, correcting real deficiency (smokers, alcohol-dependent, low-produce diets, malabsorption, dialysis) matters, and regular supplementation modestly shortens colds — yet the Linus Pauling megadose thesis that grams a day prevent or cure colds and cancer is wrong: the body saturates near 200 mg a day and excretes the rest, Cochrane finds no cold-prevention benefit in ordinary life (only a modest duration trim, plus a real prevention signal confined to extreme physical stress like marathoners and soldiers), the intr

Why Moderate

Moderate Evidence because the entry's verdict blends parts of very different strength. The saturation pharmacokinetics (body plateaus near 200 mg, excretes the excess) and the general-population cold-prevention null are high-confidence, and the essential-nutrient floor is effectively undisputed — but the claims that make vitamin C contested enough to need an entry sit at Moderate or below: the cold-duration benefit is modest, the extreme-stress prevention signal is confined to a specific subgroup, the oral cancer claim is refuted, and the IV cancer claim is early-phase and unproven. The overall entry inherits the confidence of its load-bearing therapeutic and harm claims, which is Moderate.

NOT Foundational because, although the essential-nutrient floor is axiomatic, the entry's actual content is a live both-ways tension — real deficiency value versus an unsupported megadose thesis — carrying clinical and commercial judgement rather than a single undisputed axiom.

NOT Strong because the therapeutic anchors that matter for the megadose debate are not gold-standard positives: the duration benefit is small, the prevention benefit is subgroup-confined, the IV cancer claim lacks any outcome trial, and the kidney-stone harm is observational. Only the saturation physiology, the general-population prevention null, and the essential floor reach high confidence, and the entry marks those explicitly rather than letting them lift the whole verdict.

The per-claim split (read this, not just the headline):
• Vitamin C is essential; deficiency causes scurvy: Strong (undisputed physiology).
• Body saturates near 200 mg a day, excretes the excess: Strong (controlled pharmacokinetics).
• No cold prevention in the general population: Moderate (large pooled RCTs, Cochrane).
• Modest cold-duration benefit; extreme-stress prevention signal: Moderate (real but small / subgroup-confined).
• Oral-megadose cancer cure: Experimental — effectively refuted (two RCTs).
• IV-C cancer benefit: Emerging-to-Experimental (mechanism plus early-phase, no survival trial).
• Kidney-stone risk in men: Moderate (large prospective cohort, male-specific).

Practical takeaway

The framing to hold: food-first, then correct real deficiency, and stop there. Vitamin C is essential and cheap deficiency correction is worthwhile, but past roughly 200 mg a day the body plateaus and excretes the rest. Grams a day do not prevent colds in ordinary life, and the intravenous-C cancer story is preclinical hope, not proven human survival.

Get it from food first. A diet with fruit and vegetables comfortably prevents deficiency in most people. Whole-food intake is the default; supplements are for closing a genuine gap, not for stacking on top of an already-replete diet.

Correct real deficiency — this is where supplementation earns its place.
• Higher-risk groups: smokers, the alcohol-dependent, people on low-produce diets, malabsorption, and dialysis patients are the populations where repletion genuinely matters. A modest supplemental dose, not grams, closes the gap.

Don't take it for the megadose reasons.
• General cold prevention: in ordinary life, regular supplementation does not lower how often you catch colds. It modestly shortens duration if taken regularly beforehand, and starting it after symptoms begin is not reliably effective. For the specific dosing-and-timing detail, see common_cold_prevention_and_treatment.
• The one real prevention exception: people under extreme acute physical stress — marathoners, skiers, soldiers on heavy cold-weather exertion — do show a genuine prevention signal (roughly halved incidence). This is a narrow, defined subgroup, not a licence for the general "take grams for immunity" claim.
• Cancer: oral megadosing does not extend survival (two RCTs). Intravenous-C is a direct-pay clinic market resting on mechanism and early-phase trials with no survival-outcome proof; do not present it as a treatment, and never let it displace or delay evidence-based cancer care.

Respect the ceiling and the downside.
• Past ~200 mg a day you are mostly paying for expensive urine. Sustained oral dosing above the plateau does not meaningfully raise plasma in normal physiology.
• Men at kidney-stone risk should avoid gram-level supplements. The near-doubling of stone risk is a real, mechanistically-grounded downside; this is the counterweight to "water-soluble so harmless."

Evidence detail

Why This Entry Exists

Vitamin C is the original megadose supplement, and it carries a specific historical wound: Linus Pauling, a double Nobel laureate, spent his later career arguing that grams a day would prevent the common cold and, with Ewan Cameron, cure advanced cancer. The authority of the man gave the claim a half-life that the evidence never earned. So this entry has to do two opposite jobs at once — defend a genuinely essential nutrient and its real deficiency-correction value against a lazy "it's just marketing" dismissal, and dismantle the megadose thesis that the same molecule is still used to sell.

The failure modes run in both directions. Over-claim it and a healthy person swallows grams a day for immunity they will urinate out, or a cancer patient reaches for an intravenous-C clinic on the strength of a mechanism that has never produced a survival trial. Under-claim it and you miss that deficiency is real and cheap to fix, that regular supplementation genuinely trims cold duration, and that there is a real cold-prevention signal in people under extreme acute physical stress. The trap in the middle is that a genuine mechanistic signal — pharmacologic ascorbate acting as a pro-oxidant prodrug — keeps getting presented as if it were a proven human outcome. It is not. That mechanism-versus-outcome split is the spine of the whole entry.

What bad advice this protects against, in all directions:
• "Take grams of vitamin C to avoid catching colds" → in the general population regular supplementation does NOT reduce cold incidence (Cochrane, 29 comparisons, 11,306 people); it modestly shortens duration, and the only prevention signal is confined to extreme physical stress (marathoners, skiers, soldiers).
• "More is better — load up during cold season" → the body saturates: oral absorption is complete only up to ~200 mg, plasma plateaus near 200 mg a day, and at single doses of 500 mg and above the absorbed excess is excreted in urine. Past the plateau you are paying for expensive urine.
• "High-dose vitamin C cures cancer" → the Pauling-Cameron oral-megadose claim was refuted by two Mayo Clinic RCTs; the affirmative cure claim has never been replicated in a rigorous trial.
• "Intravenous vitamin C cures cancer — the clinics prove it" → IV-C rests on preclinical mechanism (extracellular hydrogen peroxide as a pro-oxidant prodrug) plus mostly single-arm early-phase trials focused on safety and quality-of-life; there is no confirmatory survival outcome trial.
• "It's water-soluble, so megadosing is harmless" → gram-level supplements roughly double incident kidney-stone risk in men, because ascorbate is partly metabolised to oxalate; harmless is the wrong frame.
• "Vitamin C is a scam, skip it" → the reverse over-correction; deficiency is real and matters, correcting it is cheap and worthwhile, and it genuinely trims cold duration.

This entry owns the food-first plus deficiency-correction framing and the megadose and IV-C debunk. It defers cold-specific dosing and timing to common_cold_prevention_and_treatment, and the general supplement-form, elemental-dose and bioavailability mechanics to supplement_form_elemental_dose_and_bioavailability. It states those boundaries and routes there rather than re-arguing them.

Evidence

Organised by claim, with the tier signal inline. The saturation pharmacokinetics and the general-population cold-prevention null are the firmest parts; the cancer story splits sharply between a refuted oral claim and an unproven IV one — read the tiers, not just the thesis.

The essential-nutrient floor: vitamin C is required, and deficiency correction is real.

1. Humans cannot synthesise vitamin C, deficiency causes scurvy, and correcting real deficiency matters. Because humans lack a functional gene for the final step of ascorbate synthesis, dietary intake is obligatory, and frank deficiency produces scurvy. Correcting genuine deficiency — in smokers, the alcohol-dependent, people on low-fruit-and-vegetable diets, malabsorption, and dialysis — is worthwhile and cheap. This is the floor the whole entry sits on, and the reason "vitamin C is a scam" is the wrong over-correction. (Foundational human physiology; consistent with the Levine et al. pharmacokinetic work below that established the RDA. Strong for the essential-nutrient claim — it is undisputed biochemistry, not a contested supplement claim; no seller interest in the floor.)

The general-population cold-prevention claim fails — with one real exception.

2. Regular vitamin C does NOT prevent colds in the general population, but roughly halves incidence under extreme physical stress, and modestly shortens duration. Across 29 comparisons in 11,306 participants, regular supplementation gave no reduction in common-cold incidence in the general population. But in five trials of people under extreme acute physical stress — marathon runners, skiers, and soldiers on subarctic exercise — it roughly halved incidence (pooled relative risk 0.48). Separately, regular supplementation modestly shortened cold duration: about 8% in adults and about 14% in children. Therapeutic dosing started after symptom onset was not reliably effective. (Hemilä H & Chalker E, "Vitamin C for preventing and treating the common cold," Cochrane Database of Systematic Reviews 2013, CD000980.pub4, updated PMC8078152. Moderate — large pooled RCT evidence; the general-population prevention claim is null, the duration effect is modest and real, and the prevention benefit is confined to a specific extreme-stress subgroup. Cochrane review, no commercial sponsor; directly refutes the "take grams to avoid colds" pitch.)

The pharmacokinetic ceiling: the body saturates and excretes the excess.

3. Vitamin C pharmacokinetics saturate near 200 mg a day, and the absorbed excess above that is excreted in urine. In a controlled depletion-repletion study in healthy volunteers, single-dose oral bioavailability was complete up to about 200 mg; steady-state plasma concentration was a sigmoid function of dose with the steep segment between 30 and 100 mg; plasma reached near-maximum at 200 mg a day and fully saturated at 1000 mg a day; and at single doses of 500 mg and above, bioavailability fell and the absorbed excess was excreted in urine. This is the pharmacological basis for the RDA and the direct mechanistic refutation of oral megadosing. (Levine M et al., "Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance," PNAS 1996;93(8):3704-3709, PMID 8623000. Strong for the physiology — a controlled pharmacokinetic study; the "body saturates and excretes the excess" mechanism is well established. NIH intramural, NIDDK; no industry interest in demonstrating a low ceiling, which is what makes this the anti-hype receipt.)

The oral-megadose cancer claim: refuted.

4. The Pauling-Cameron high-dose vitamin C cancer-survival claim was refuted by two Mayo Clinic RCTs. The claim that 10 g a day extends survival in advanced cancer was tested in two randomised controlled trials: Creagan et al. 1979 (n=150 enrolled, 123 evaluable) and Moertel et al. 1985 (n=100, colorectal), neither of which showed a survival advantage. Defenders note a route-and-duration difference — Cameron used long-term intravenous plus oral dosing, whereas the Mayo trials used oral dosing over a median of roughly 2.5 months — which is a legitimate methodological caveat, but the affirmative oral-megadose cure claim has never been replicated in a rigorous trial. (Creagan ET et al., NEJM 1979;301:687; Moertel CG et al., NEJM 1985;312:137; reviewed in Front Physiol 2018;9:1182 and a Frederick National Laboratory summary. Experimental for the cancer-cure claim — effectively refuted for oral megadosing; the IV route remains unproven, not proven. Pauling ran the Linus Pauling Institute and the pro-vitamin-C camp framed the Mayo failures as suppression; cui bono runs both ways, but the RCTs are the higher-quality evidence.)

The IV-vitamin-C cancer market: mechanism and early-phase signal, no outcome proof.

5. Intravenous vitamin C in cancer rests on preclinical mechanism plus mostly single-arm early-phase trials, with no confirmatory survival benefit. Only pharmacologic — not physiologic — ascorbate concentrations, achievable by the intravenous route but not by oral dosing, generate extracellular hydrogen peroxide that acts as a pro-oxidant prodrug in vitro and in animals. That is the mechanistic rationale. The clinical evidence is mostly single-arm Phase I/II trials focused on safety and quality-of-life: a systematic review of 23 trials (385 patients) found only one randomised trial (in ovarian cancer) with a progression-free-survival signal. Encouraging, but not outcome-trial proof — the roughly 10,000-patients-a-year IV-C clinic market outpaces the evidence. (Nauman G, Gray JC, Parkinson R, Levine M, Paller CJ, "Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials," Antioxidants 2018, PMC6071214; a Phase II pancreatic trial (University of Iowa, 2024) and a metastatic castration-resistant prostate cancer docetaxel Phase II (Cancer Res Commun 2024) remain early-phase. Emerging-to-Experimental — real mechanistic and early-phase signal, no confirmatory Phase III survival benefit; the classic surrogate-and-mechanism-versus-outcome gap. IV-C clinics are a direct-pay market with strong incentive to overstate; the good safety profile is what sustains the market in the absence of efficacy proof.)

The harm counterweight: kidney stones in men.

6. Gram-level vitamin C supplements roughly double kidney-stone risk in men. In a prospective cohort of 23,355 men followed for 11 years (436 incident stones), supplements of about 1000 mg a day were associated with roughly double the incident kidney-stone risk (hazard ratio near 2), because ingested ascorbate is partly metabolised to oxalate and excreted, favouring calcium-oxalate stone formation. The effect was seen in men and not consistently in women. (Thomas LDK et al., "Ascorbic Acid Supplements and Kidney Stone Incidence Among Men," JAMA Internal Medicine 2013;173(5):386; meta-analysis PMID 30178451. Moderate — a large prospective cohort, so association rather than causation, with a plausible oxalate mechanism; consistent enough to warn men at stone risk. Swedish cohort, no supplement-industry funding; a genuine harm counterweight to the "water-soluble so harmless" framing.)

Mechanism

This entry owns the saturation ceiling and the pharmacologic-versus-physiologic distinction, not the general label-literacy and elemental-dose framework, which is deferred to supplement_form_elemental_dose_and_bioavailability. What follows is only enough mechanism to make the megadose debunk and the IV caveat intelligible.

Why "essential" and "megadose" are not the same argument. Vitamin C is an obligatory dietary nutrient — humans cannot make it, and without it the collagen-hydroxylation and antioxidant roles fail, producing scurvy. That establishes a floor: everyone needs some, and the deficient need repletion. But a floor is not a dose-response ramp. Once tissues and plasma are replete, adding more does not push a saturated system to do more work. The mass-market pitch quietly slides from "you need it" (true) to "more of it does more" (false), and the pharmacokinetics are where that slide breaks.

Why the body excretes the excess. Intestinal absorption and renal handling of ascorbate are both saturable. Oral absorption is essentially complete only up to about 200 mg in a single dose; above that the absorbed fraction falls, and once plasma passes its plateau the kidney excretes the surplus. So sustained oral dosing above roughly 200 mg a day cannot meaningfully raise steady-state plasma in normal physiology — the system is already near its ceiling. This is the direct mechanistic reason grams a day buy little beyond expensive urine. The honest qualifier: this is a whole-body and plasma saturation argument; tissue-level and single-dose kinetics are more nuanced, so "everything above 200 mg is literally wasted" overstates a real effect. The defensible line is that sustained oral dosing does not meaningfully exceed the plasma plateau.

Why the IV cancer argument is a different case — and why oral saturation does NOT refute it. This is the split that gets flattened. The saturation ceiling applies to oral dosing. The intravenous route bypasses gut absorption and can drive plasma to pharmacologic concentrations that oral dosing cannot reach, and only at those pharmacologic concentrations does ascorbate flip from antioxidant to a pro-oxidant prodrug generating extracellular hydrogen peroxide with selective activity against tumour cells in preclinical models. So the oral-saturation pharmacokinetics do NOT by themselves refute IV-C. The correct refutation of the IV cancer claim is different and narrower: the absence of a Phase III survival outcome trial. Mechanism and early-phase safety data are real; a proven human survival benefit is not. Keep those two arguments separate, or you refute IV-C with the wrong tool and hand its promoters an easy rebuttal.

Why megadosing carries a real downside. Ingested ascorbate is partly metabolised to oxalate, which the kidney excretes. At gram-level intakes the extra urinary oxalate favours calcium-oxalate stone formation, which is the mechanistic basis for the observed near-doubling of stone risk in men. "Water-soluble, therefore harmless" ignores this metabolic tail.

Risks And Contraindications

• The main risk in healthy people is opportunity cost and false reassurance, not toxicity. Vitamin C is generally well tolerated at ordinary doses. The realistic harm from megadosing in a replete person is money spent on a supplement the body excretes, plus the false confidence of "doing something" for immunity that the general-population evidence does not support.
• Kidney stones in men — a real, mechanistically-grounded harm. Gram-level supplements (about 1000 mg a day) roughly doubled incident kidney-stone risk in a large male cohort, because ascorbate is partly metabolised to oxalate favouring calcium-oxalate stones. Keep the honesty guardrails: this is observational (association, not proven causation) and largely male-specific — do not present it as certain, and do not extend it equally to women, where the signal is not consistent. But it is enough to warn men at stone risk off gram-level dosing.
• Do not let IV-vitamin-C displace real cancer treatment. The IV-C cancer market rests on preclinical mechanism and early-phase, mostly single-arm trials with no survival-outcome proof. Its safety profile is genuinely good, which is exactly what sustains the market absent efficacy — but a patient choosing an IV-C clinic over, or alongside as a substitute for, evidence-based oncology is the dangerous over-claim to avoid.
• Do not overstate novelty or harm. Vitamin C is an old, well-characterised nutrient, not a novel longevity compound with unknown long-term safety; the honest risk profile is the kidney-stone tail in men and the opportunity cost of megadosing, not a mystery hazard.
• Keep the prevention signal at its real, narrow scope. The extreme-physical-stress cold-prevention benefit is real. Do not flatten "no prevention in the general population" into an absolute "vitamin C never prevents colds" — the subgroup exception is genuine.
• Keep the oral and IV arguments separate. The oral-saturation pharmacokinetics do not refute IV-C; the refutation of the IV cancer claim is the missing survival trial. Do not surface the wrong argument against the wrong target.

Controversy

Nature: an essential nutrient with genuine deficiency-correction value wrapped in a decades-old megadose thesis — Pauling's grams-a-day-prevents-and-cures claim — that the evidence does not support, with error possible at both poles: over-claiming megadose and IV-C benefit on one side, and dismissing vitamin C as a scam on the other.

Position A — "Vitamin C is essential and genuinely useful." The defended-floor take.
• Best evidence: humans cannot synthesise it and deficiency causes scurvy; correcting real deficiency (smokers, alcohol-dependent, low-produce diets, malabsorption, dialysis) matters; regular supplementation modestly shortens colds (about 8% in adults, about 14% in children); and there is a real prevention signal under extreme physical stress (pooled relative risk 0.48). Each is real within its stated bounds.
• Where it goes wrong if overstated: it slides into "everyone should megadose for immunity," treats the extreme-stress prevention signal as a general effect, or reads the IV-C mechanism as a proven cancer treatment.

Position B — "The megadose thesis is wrong." The debunk take.
• Best evidence: regular supplementation does not reduce cold incidence in the general population; the body saturates near 200 mg a day and excretes the excess; the Pauling-Cameron cancer claim was refuted by two Mayo RCTs; the IV-C cancer market rests on mechanism and early-phase trials, not survival outcomes; and gram-level doses roughly double kidney-stone risk in men.
• Where it goes wrong if overstated: it can tip into "vitamin C is useless" or "everything above the RDA is wasted," which ignores the real deficiency-correction value, the genuine duration benefit, and the narrow but real extreme-stress prevention signal.

The funding/bias dimension — cui bono, both ways. Toward over-claiming: the pro-megadose side carries the commercial pressure. The supplement industry sells grams a day for immunity; Pauling's own Linus Pauling Institute anchored the cancer thesis and framed the Mayo failures as suppression; and the direct-pay IV-C clinic market (roughly 10,000 US patients a year) has strong incentive to present a preclinical hydrogen-peroxide mechanism and single-arm Phase II data as if they were a proven survival benefit — the textbook surrogate-and-mechanism-versus-outcome trap. Toward the corrective pole: mainstream messaging can under-emphasise that real deficiency correction genuinely matters and that the extreme-stress prevention signal is not zero. The cleanest, least-conflicted evidence — NIH pharmacokinetics, the Cochrane review, the Mayo RCTs, and the Swedish stone cohort — consistently lands in the same place.

Realised Position: Food-first, then correct real deficiency, and stop there. Vitamin C is essential and cheap deficiency correction is worthwhile, but megadosing is not: past roughly 200 mg a day the body plateaus and excretes the rest, grams a day do not prevent colds in ordinary life (only a modest duration trim, plus a real prevention signal under extreme physical stress), and the IV-C-cures-cancer story is preclinical hope, not proven human survival. Very high doses carry a real downside — kidney stones in men. The separation to name and hold: a genuine mechanistic signal, pharmacologic ascorbate as a pro-oxidant prodrug, is NOT a proven survival benefit.

Cross-Pillar Connections

Vitamin C is a diet/supplement topic with an immune tail and a debunk backbone, so its connections span the supplement-literacy, cold, and evidence-method lines.
• Conditions (common_cold_prevention_and_treatment): owns the cold-specific dosing, timing, and treatment detail; this entry holds only the headline that regular supplementation does not prevent colds in the general population (with the extreme-stress exception and the modest duration benefit) and defers the specifics there.
• Supplements (supplement_form_elemental_dose_and_bioavailability): owns the general label-literacy, elemental-dose and bioavailability framework; this entry holds only the vitamin-C-specific saturation reality (absorption complete to ~200 mg, plasma plateau, excreted excess) and defers the general principle there.
• Supplements (universal_nearuniversal_supplementation): the reference point for which supplements clear the bar for near-universal use — vitamin C clears it only as deficiency correction in defined groups, not as a universal megadose, which is the contrast this entry draws.
• Foundations (publication_bias_and_evidence_distortion): the mechanism behind the selective-citation, mechanism-as-outcome, and single-authority patterns that have kept the megadose and IV-C claims alive past their evidence.
• Conditions (immune_function_cross_pillar_optimisation): the reference for what actually moves immune function across pillars — relevant to reading the "vitamin C for immunity" pitch critically against real levers.

What would change our mind

Industry bias note

Sources (6)

• Levine M et al. (1996). "Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance." PNAS 93(8):3704-3709, pubmed.ncbi.nlm.nih.gov/8623000↗/" target="_blank" rel="noopener">PMID 8623000↗. (NIH intramural, NIDDK; no seller interest in a low ceiling — the anti-hype receipt.) — single-dose oral bioavailability complete to ~200 mg; steady-state plasma sigmoid, steep segment 30-100 mg; near-maximum at 200 mg/day, full saturation at 1000 mg/day; at single doses of 500 mg+ bioavailability falls and the absorbed excess is excreted in urine.
• Hemilä H & Chalker E (2013). "Vitamin C for preventing and treating the common cold." Cochrane Database of Systematic Reviews, CD000980.pub4 (updated PMC8078152). (Cochrane; no commercial sponsor.) — no reduction in cold incidence in the general population (29 comparisons, 11,306 participants); pooled relative risk 0.48 for incidence in 5 extreme-physical-stress trials; duration shortened ~8% in adults, ~14% in children; therapeutic dosing after onset not reliably effective.↗
• Creagan ET et al. (1979). NEJM 301:687; Moertel CG et al. (1985). NEJM 312:137 (colorectal, n=100). (Mayo Clinic RCTs; framed as suppression by the pro-vitamin-C camp, but the higher-quality evidence.) — two randomised trials of high-dose oral vitamin C in advanced cancer, neither showing a survival advantage; reviewed in Front Physiol 2018;9:1182 and a Frederick National Laboratory summary, which note the IV-versus-oral route caveat.↗
• Nauman G, Gray JC, Parkinson R, Levine M, Paller CJ. (2018). "Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials." Antioxidants, PMC6071214. (Academic systematic review; IV-C clinics are a direct-pay market with incentive to overstate.) — 23 trials, 385 patients, mostly single-arm Phase I/II on safety and quality-of-life; only one randomised trial (ovarian) with a progression-free-survival signal; a Phase II pancreatic trial (University of Iowa, 2024) and an mCRPC docetaxel Phase II (Cancer Res Commun 2024) remain early-phase.↗
• Thomas LDK et al. (2013). "Ascorbic Acid Supplements and Kidney Stone Incidence Among Men." JAMA Internal Medicine 173(5):386; meta-analysis pubmed.ncbi.nlm.nih.gov/30178451↗/" target="_blank" rel="noopener">PMID 30178451↗. (Swedish cohort; no supplement-industry funding — a conflict-clean harm counterweight.) — 23,355 men, 11-year follow-up, 436 incident stones; ~1000 mg/day supplements associated with roughly double the incident kidney-stone risk (hazard ratio near 2); effect in men, not consistently in women; oxalate mechanism.
• Funding notation: the load-bearing counter-claims (saturation ceiling; no general-population cold prevention; kidney-stone harm) come from independent academic and NIH sources with no seller interest, and vitamin C's cheap, off-patent status means there is no organised interest in suppressing it — so those claims are trustworthy. The most commercially-motivated claims (megadose for immunity; the IV-C cancer market's mechanism-as-outcome framing) are exactly the ones the entry marks and hedges. The bias vector runs almost entirely toward over-claiming benefit.*↗

Related entries